IP Library › Granted Patent US 11,976,295
Granted Patent B2
US 11,976,295 · App. 18/153,974 · Granted May 7, 2024

Media for stem cell proliferation and induction

Inventors: Cynthia Bamdad (Waltham, MA); Benoit Smagghe (Waltham, MA)
Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
C12N5/0607C12N5/0037C12N5/0056C12N5/0606C12N2500/90C12N2501/00C12N2501/10C12N2501/115C12N2501/15C12N2501/727C12N2501/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,976,295
App. No.
18/153,974
Granted
May 7, 2024
Kind
B2
Abstract

The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.

Claims (19)

1. A cell culture media for growth, maintenance, and induction of reversion to a less mature state of a cell comprising a recombinant NME7 protein that comprises a nucleotide diphosphate kinase (NDPK) A domain and an NDPK B domain and does not comprise a targeting sequence.

2. The cell culture media according to claim 1 , wherein the cell is a stem or progenitor cell.

3. The cell culture media according to claim 1 , wherein the cell is a mature, somatic, or progenitor cell.

4. The cell culture media according to claim 1 , wherein the cell is human.

5. The cell culture media according to claim 1 , wherein the cell culture media does not comprise basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-beta), or both.

6. The cell culture media according to claim 1 , wherein the cell culture media is free of serum.

7. The cell culture media according to claim 1 , wherein the cell culture media further comprises insulin, selenium, transferrin, L-ascorbic acid, or one or more non-essential amino acids.

8. The cell culture media according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 25-33 kilodaltons (kDa).

9. The cell culture media according to claim 1 , further comprising an inhibitor of a rho associated kinase.

10. The cell culture media according to claim 1 , further comprising an activator of one or more signaling proteins in the PI3K or RAC pathway and in the absence of a rho kinase inhibitor.

11. The cell culture media according to claim 1 , further comprising nucleic acids that suppress expression of NME1 or NME2.

12. The cell culture media according to claim 1 , further comprising other growth factors.

13. The cell culture media according to claim 12 , wherein the other growth factors are FGF-2 and/or TGF-beta.

14. The cell culture media according to claim 1 , wherein the recombinant NME7 is the only growth factor in the cell culture media.

15. The cell culture media according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 30 kilodaltons (kDa).

16. The cell culture media according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 31 kilodaltons (kDa).

17. The cell culture media according to claim 1 , wherein the recombinant NME7 is characterized by a molecular weight of about 33 kilodaltons (kDa).

18. The cell culture media according to claim 1 , wherein the recombinant NME7 comprises an alternative splice isoform having an amino acid sequence of SEQ ID NO: 39, 41, 59, or 61.

19. The cell culture media according to claim 1 , wherein the cell culture media further comprises an activator of one or more signaling proteins in the PBK or RAC pathway.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: BAMDAD, CYNTHIA; SMAGGHE, BENOIT
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 062860/0340 →
Continuity (16)
Division 14254749 · Apr 16, 2014
Continuation In Part PCTUS2012060684 · Oct 17, 2012
Provisional Application 61693712 · Aug 27, 2012
Provisional Application 61684654 · Aug 17, 2012
Provisional Application 61683155 · Aug 14, 2012
Provisional Application 61679021 · Aug 2, 2012
Provisional Application 61677442 · Jul 30, 2012
Provisional Application 61675264 · Jul 24, 2012
Provisional Application 61675292 · Jul 24, 2012
Provisional Application 61673617 · Jul 19, 2012
Provisional Application 61671558 · Jul 13, 2012
Provisional Application 61671588 · Jul 13, 2012
Provisional Application 61622422 · Apr 10, 2012
Provisional Application 61618578 · Mar 30, 2012
Provisional Application 61548199 · Oct 17, 2011
Related Publication 20230287338A1 · Sep 14, 2023
Cited By (3)
US 12,195,728 US 12,415,868 US 12,491,259